Gartner heads into its Q1 2026 earnings — confirmed for May 28 — with short interest at its highest level in months and a broad analyst target-price reset still playing out beneath the surface.
Short interest is the primary tension here. At 14.1% of free float, it has jumped sharply since late April, up from roughly 11.5% in mid-April. That move — approximately 15% in shares short over the past month — makes Gartner one of the more meaningfully shorted names in its peer group. The ORTEX short score has climbed to 63.1 out of 100 and has accelerated over the past two weeks, rising from 57 in late April as the new short positions were added. Days to cover stand at just over 6, so unwinding that position would take time at typical trading volumes.
The borrow market does not suggest any imminent mechanical pressure on short sellers. Cost to borrow is only 0.46% — cheap and essentially unchanged over the past month. Borrow availability is not tight, meaning there is ample capacity for additional shorts if the thesis deepens. Options positioning has turned more defensive than usual. The put/call ratio has risen to 0.69, approximately 1.7 standard deviations above its 20-day average of 0.55 — a move driven largely by the past two weeks, when the PCR was running in the mid-0.60s after spending most of March and early April below 0.50. Taken together, the shorts are building and options traders are hedging, yet borrow conditions show no squeeze pressure.
The Street has spent the past several months marking down targets in a coordinated, if reluctant, retreat. The direction of travel is uniformly lower: Morgan Stanley cut its target to $183 today while holding Equal-Weight, and RBC followed to $160, also Sector Perform. Goldman trimmed to $171 last week, maintaining Neutral. Barclays and Wells Fargo had already reduced their targets in April, with Wells holding an Underweight at $140 — the most bearish standing target on the board. Against a current price of $149.49, the mean analyst target of $167 implies roughly 12% upside, but that consensus figure is being actively dragged lower with every revision. The analyst recommendation spread — with a factor rank of just 8 out of 100 on rec divergence — shows little disagreement on direction: nearly everyone is cautious, just not yet negative. Valuation multiples have compressed in tandem, with the P/E contracting nearly a full turn over the past 30 days to 10.7x and Price/Book down about one multiple point to 9.4x.
The bear case draws on two concerns that have become increasingly concrete. Flat EBITDA margins — projected around 23.5% for FY26 — are below consensus expectations, and the Consulting segment has a history of sharp revenue cyclicality in downturns. The bigger structural worry is GenAI disintermediation: if enterprise clients can increasingly self-serve on the advisory and research functions Gartner monetises, the growth premium embedded in its subscription model erodes. The bull case rests on the Insights segment, which now generates 82% of revenue and has compounded at double digits for years. On EPS momentum, Gartner scores in the 80th percentile over 30 days and the 74th on EPS surprise, suggesting estimates have been beaten reliably even as the stock de-rates. The EV/EBIT score ranks in the 85th percentile, indicating valuation is not stretched on an earnings-based measure even after the recent compression.
The stock is down 41% year-to-date — a severe re-rating — while its most correlated peer ACN is roughly flat on the week. CTSH fell nearly 6% over the same period and EPAM dropped about 4%, suggesting the wider IT services complex is under pressure rather than Gartner-specific stress. The May 28 earnings call is the next clearing event. Whether the shorts maintain their newly rebuilt positions through the print — and whether the options market's growing defensiveness proves warranted — is what the tape will answer over the next three weeks.
See the live data behind this article on ORTEX.
Open IT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
